No significant changes in lipids (total cholesterol, HDL cholesterol, LDL cholesterol, or triglycerides), glucose, insulin, or the homeostasis model assessment of insulin resistance (HOMA-IR) were observed overall (Table 2) or in any sub-group 24 weeks after initiating telmisartan therapy. This evidence concerns the gene INS and Insulin resistance.